Andrew Dunbar, BM
Department of Hematopoietic Biology & Malignancy, Division of Cancer Medicine
Licenses & Certifications
| 2023 | Physicians License |
| 2023 | Physician License |
| 2023 | Physicians License |
| 2018 | American Board of Internal Medicine |
| 2015 | American Board of Internal Medicine |
Experience & Service
Editorial Activities
Invited reviewer, Hematology, 2022 - Present
Invited reviewer, Haematologica, 2021 - Present
Invited reviewer, Blood, 2020 - Present
Invited reviewer, Leukemia, 2020 - Present
Honors & Awards
| 2018 | HemeOnc Today, Next Gen Innovator |
| 2017 | Awardee, National Institute of Health Loan Repayment Program |
| 2012 | Cor et Manus Award for Extraordinary Community Service, New York Medical College |
| 2010 | Chair, Clinical Student Medical Liaison Committee, New York Medical College |
| 2007 | Annual Meeting Travel Award, American Society of Hematology |
| 2002 | Vanderbilt University Music Performance Scholarship and Dean's List, Vanderbilt University |
Selected Presentations & Talks
Regional Presentations
- 2018. Dr. Seema Gupta Memorial Lectureship. Invited, US.
National Presentations
- 2022. European Society of Hematology Intl. Conf. Invited. Virtual, Virtual, US.
- 2022. Korean Society of Hematology Intl. Conf. Invited. Virtual, Virtual, US.
- 2022. The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs). Poster. 64th American Society of Hematology Conference. New Orleans, LA, US.
- 2022. Reversible Activation Shows an Essential Requirement for Jak2V617F in Myeloproliferative Neoplasms. Invited. American Society of Hematology Conference. New Orleans, LA, US.
- 2020. Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms. Invited. The 62nd American Society of Hematology Conference. Virtual, Virtual, US.
- 2019. Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trial. Poster. 61st American Society of Hematology. Orlando, FL, US.
- 2019. Extended Mutational Profiling by MSK-IMPACT Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy. Invited. 61st American Society of Hematology. Orlando, FL, US.
- 2019. Role of hepcidin and TfR2 in dysregulated iron metabolism during erythythropoiesis in polycythemia vera. Invited. 61st American Society of Hematology. Orlando, FL, US.
- 2018. New Insights into the Understanding of Thrombosis & Hemorrhage in Myeloproliferative Neoplasms. Invited. Charleston, SC, US.
- 2013. What Lies Beneath: Sub-Mucosal Cancer Causing Dysphagia. Poster. Annual American College of Gastroenterology Conference. San Diego, CA, US.
- 2008. Frequent Detection of C-Cbl Homozygous Mutation in Secondary Myelogeneous Leukemia Transformed from MDS/MPD with Chromosome 11q Uniparental Disomy. Invited. 50th American Society of Hematology Annual Meeting, US.
- 2008. SNP-A Karyotyping Provides a Clonal Molecular Marker and Is Associated with a High Incidence of Segmental Uniparental Disomy in Patients with CMML. Poster. 50th American Society of Hematology Annual Meeting, US.
- 2007. SNP-A karyotyping demonstrates a high incidence of segmental uniparental disomy in patients with CMML and shows impact of newly identified chromosomal aberrations on clinical course. Poster. 49th American Society of Hematology Annual Meeting, US.
International Presentations
- 2023. Myeloid Malignancy Workshop. Mount Sinai, US.
- 2017. Evaluation of JAK2/ASXL1 Phenotype and Response to Ruxolitinib in Myeloprolierative Neoplasms. Poster. 4th Annual Summit in Hematologic Malignancy. Whistler, CA.
- 2007. SNP-array-based detection of the minimally delineated region of chromosome 5q in patients with malignant myeloid diseases. Poster. European Student’s Conference. Berlin, US.
Grant & Contract Support
| Date: | 2023 - Present |
| Title: | Investigating High-Risk Epigenetic Modifying Alterations on JAK2VF Dependency and Fibrotic Progression in Myeloproliferative Neoplasms (MPNs) |
| Funding Source: | NIH |
| Role: | PI |
| ID: | K08HL169905-01 |
| Date: | 2021 - Present |
| Title: | Pegylated Interferon on clonal trajectory and inflammatory cytokine production in MPN patients |
| Funding Source: | NIH |
| Role: | Co-PI |
| ID: | R21CA267632 |
| Date: | 2021 - 2023 |
| Title: | Inflammation and Predisposition to FPD/HM |
| Funding Source: | C01 Evans MDS FIRE Grant |
| Role: | Co-PI |
| Date: | 2019 - 2023 |
| Title: | Functional Contribution of JAK2V617F in the Maintenance of Myeloproliferative Neoplasms |
| Funding Source: | William Raveis Charitable Fund Fellow of the Damon Runyon Cancer Research Foundation |
| Role: | PI |
| Date: | 2019 |
| Title: | Fellow Award |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| Date: | 2018 |
| Title: | Award in Hematologic Oncology Research |
| Funding Source: | Mortimer J. Lacher Fellowship of the Lymphoma Foundation |
| Role: | PI |
| Date: | 2017 - 2019 |
| Title: | Clinical and Translational Cancer Research Fellowship |
| Funding Source: | American Association of Cancer Research (AACR) |
| Role: | PI |
| Date: | 2017 - 2018 |
| Title: | Conquer Cancer Foundation Young Investigator Award |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | PI |
| Date: | 2016 - 2018 |
| Title: | Predoctoral National Research Service Award (NRSA) |
| Funding Source: | NIH |
| Role: | PI |
| ID: | T32-CA009207 |
Selected Publications
Peer-Reviewed Articles
- Marvin-Peek, J, DiNardo, C, Loghavi, S, Ravandi-Kashani, F, Borthakur, G, Daver, N, Kadia, TM, Jabbour, EJ, Dunbar, A, Tang, G, Short, NJ, Haddad, FG, Abbas, HA, Kugler, E, Maiti, A, Issa, GC, Takahashi, K, Bhalla, K, Pemmaraju, N, Alvarado, Y, Shpall, E, Popat, UR, Ramdial, JL, Champlin, RE, Kantarjian, HM, Garcia-Manero, G, Senapati, J. Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy. Cancer 132(10), 2026. e-Pub 2026. PMID: 42089434.
- Fiskus W, Masarova L, Mill CP, Birdwell CE, Das K, Hou H, Davis JA, Jain A, Malovannaya A, Manshouri T, Dunbar A, Sharma S, Kadia TM, DiNardo CD, Bose P, Pemmaraju N, Loghavi S, Su X, Rampal RK, Torngren M, Bhalla KN. Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase. Blood Adv 9(21):5598-5609, 2025. e-Pub 2025. PMID: 40829105.
- Osman AM, Remsik J, Snyder J, Wijetunga NA, Manoranjan B, Nobre AR, Freret M, Guber D, Chabot K, Piedrafita-Ortiz S, Tong X, Wang H, Li MJ, Dunbar AJ, Levine RL, Yang JT, Boire A. Autocrine CXCL1-CXCR2 Signaling Mediates Leptomeningeal Resistance to Radiation Therapy. bioRxiv, 2025. e-Pub 2025. PMID: 40060386.
- Fiskus, WC, Mill, CP, Bose, P, Masarova, L, Pemmaraju, N, Dunbar, A, Birdwell, C, Davis, JA, Das, K, Hou, H, Manshouri, T, Jain, A, Malovannaya, A, Philip, K, Alhamadani, N, Matthews, A, Lin, K, Flores, L, Loghavi, S, DiNardo, C, Su, X, Rampal, R, Bhalla, K. Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML. Blood 145(6):612-624, 2025. e-Pub 2025. PMID: 39561280.
- Bowman, RL, Dunbar, A, Mishra, T, Xiao, W, Waarts, MR, Maestre, IF, Eisman, SE, Cai, L, Mowla, S, Shah, N, Youn, A, Bennett, L, Fontenard, S, Gounder, S, Gandhi, A, Bowman, M, O'Connor, K, Zaroogian, Z, Sánchez-Vela, P, Martinez Benitez, AR, Werewski, M, Park, Y, Csete, I, Krishnan, A, Lee, D, Boorady, N, Potts, CR, Jenkins, MT, Cai, SF, Carroll, M, Meyer, SE, Miles, LA, Ferrell, PB, Trowbridge, JJ, Levine, RL. In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy. Cancer cell 42(11):1955-1969.e7, 2024. e-Pub 2024. PMID: 39532065.
- Gotlib, J, Gerds, A, Abdelmessieh, P, Ali, H, Castells, M, Dunbar, A, Fein Revell, R, George, T, Green, S, Gundabolu, K, Hexner, E, Jain, T, Jamieson, C, Kaesberg, P, Kuykendall, A, Madanat, Y, Manchanda, N, Masarova, L, May, J, McMahon, B, Mohan, S, Nadiminti, KV, Oh, ST, Palmer, J, Patel, AB, Patel, AA, Podoltsev, N, Rein, LA, Salit, R, Talpaz, M, Wadleigh, M, Wall, S, Bergman, MA, Hochstetler, C. NCCN Guidelines® Insights. Journal of the National Comprehensive Cancer Network : JNCCN 22(2), 2024. e-Pub 2024. PMID: 38862005.
- Izzo, F, Myers, RM, Ganesan, S, Mekerishvili, L, Kottapalli, S, Prieto, T, Eton, EO, Botella, T, Dunbar, A, Bowman, RL, Sotelo, J, Potenski, C, Mimitou, EP, Stahl, M, El Ghaity-Beckley, S, Arandela, JA, Raviram, R, Choi, DC, Hoffman, R, Chaligné, R, Abdel-Wahab, O, Smibert, P, Ghobrial, IM, Scandura, JM, Marcellino, BK, Levine, RL, Landau, DA. Mapping genotypes to chromatin accessibility profiles in single cells. Nature 629(8014):1149-1157, 2024. e-Pub 2024. PMID: 38720070.
- Freeman, R, Shahid, S, Khan, AG, Mathew, SC, Souness, S, Burns, ER, Um, JS, Tanaka, K, Cai, W, Yoo, S, Dunbar, A, Park, Y, McAvoy, D, Hosszu, KK, Levine, RL, Boelens, JJ, Lorenz, IC, Brentjens, RJ, Daniyan, A. Developing a membrane-proximal CD33-targeting CAR T cell. Journal for immunotherapy of cancer 12(5), 2024. e-Pub 2024. PMID: 38772686.
- Codilupi T, Szybinski J, Arunasalam S, Jungius S, Dunbar AC, Stivala S, Brkic S, Albrecht C, Vokalova L, Yang JL, Buczak K, Ghosh N, Passweg JR, Rovo A, Angelillo-Scherrer A, Pankov D, Dirnhofer S, Levine RL, Koche R, Meyer SC. Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable. Clin Cancer Res 30(3):586-599, 2024. e-Pub 2024. PMID: 37992313.
- Cai SF, Huang Y, Lance JR, Mao HC, Dunbar AJ, McNulty SN, Druley T, Li Y, Baer MR, Stock W, Kovacsovics T, Blum WG, Schiller GJ, Olin RL, Foran JM, Litzow M, Lin T, Patel P, Foster MC, Boyiadzis M, Collins RH, Chervin J, Shoben A, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EM. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv 8(2):429-440, 2024. e-Pub 2024. PMID: 37871309.
- Pritchard JE, Pearce JE, Snoeren IAM, Fuchs SNR, Götz K, Peisker F, Wagner S, Benabid A, Lutterbach N, Klöker V, Nagai JS, Hannani MT, Galyga AK, Sistemich E, Banjanin B, Flosdorf N, Bindels E, Olschok K, Biaesch K, Chatain N, Bhagwat N, Dunbar A, Sarkis R, Naveiras O, Berres ML, Koschmieder S, Levine RL, Costa IG, Gleitz HFE, Kramann R, Schneider RK. Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms. Cell Rep 43(1):113608, 2024. e-Pub 2024. PMID: 38117649.
- Fidler, TP, Dunbar, A, Kim, E, Hardaway, B, Pauli, J, Xue, C, Abramowicz, S, Xiao, T, O’Connor, K, Sachs, N, Wang, N, Maegdefessel, L, Levine, RL, Reilly, MP, Tall, AR. Suppression of IL-1β promotes beneficial accumulation of fibroblast-like cells in atherosclerotic plaques in clonal hematopoiesis. Nature Cardiovascular Research 3(1):60-75, 2024. e-Pub 2024. PMID: 38362011.
- Dunbar AJ, Bowman RL, Park YC, O'Connor K, Izzo F, Myers RM, Karzai A, Zaroogian Z, Kim WJ, Fernandez-Maestre I, Waarts MR, Nazir A, Xiao W, Codilupi T, Brodsky M, Farina M, Cai L, Cai SF, Wang B, An W, Yang JL, Mowla S, Eisman SE, Hanasoge Somasundara AV, Glass JL, Mishra T, Houston R, Guzzardi E, Martinez Benitez AR, Viny AD, Koche RP, Meyer SC, Landau DA, Levine RL. Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms. Cancer Discov 14(5):737-751, 2024. e-Pub 2024. PMID: 38230747.
- McCarter JGW, Nemirovsky D, Famulare CA, Farnoud N, Mohanty AS, Stone-Molloy ZS, Chervin J, Ball BJ, Epstein-Peterson ZD, Arcila ME, Stonestrom AJ, Dunbar A, Cai SF, Glass JL, Geyer MB, Rampal RK, Berman E, Abdel-Wahab OI, Stein EM, Tallman MS, Levine RL, Goldberg AD, Papaemmanuil E, Zhang Y, Roshal M, Derkach A, Xiao W. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia. Blood Adv 7(17):5000-5013, 2023. e-Pub 2023. PMID: 37142255.
- Dunbar AJ, Kim D, Lu M, Farina M, Bowman RL, Yang JL, Park Y, Karzai A, Xiao W, Zaroogian Z, O'Connor K, Mowla S, Gobbo F, Verachi P, Martelli F, Sarli G, Xia L, Elmansy N, Kleppe M, Chen Z, Xiao Y, McGovern E, Snyder J, Krishnan A, Hill C, Cordner K, Zouak A, Salama ME, Yohai J, Tucker E, Chen J, Zhou J, McConnell T, Migliaccio AR, Koche R, Rampal R, Fan R, Levine RL, Hoffman R. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis. Blood 141(20):2508-2519, 2023. e-Pub 2023. PMID: 36800567.
- Stahl M, Derkach A, Farnoud N, Bewersdorf JP, Robinson T, Famulare C, Cho C, Devlin S, Menghrajani K, Patel MA, Cai SF, Miles LA, Bowman RL, Geyer MB, Dunbar A, Epstein-Peterson ZD, McGovern E, Schulman J, Glass JL, Taylor J, Viny AD, Stein EM, Getta B, Arcila ME, Gao Q, Barker J, Shaffer BC, Papadopoulos EB, Gyurkocza B, Perales MA, Abdel-Wahab O, Levine RL, Giralt SA, Zhang Y, Xiao W, Pai N, Papaemmanuil E, Tallman MS, Roshal M, Goldberg AD. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. Am J Hematol 98(1):79-89, 2023. e-Pub 2023. PMID: 36251406.
- Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(9):1033-1062, 2022. e-Pub 2022. PMID: 36075392.
- Verachi P, Gobbo F, Martelli F, Martinelli A, Sarli G, Dunbar A, Levine RL, Hoffman R, Massucci MT, Brandolini L, Giorgio C, Allegretti M, Migliaccio AR. The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1 low Mice. Front Oncol 12:853484, 2022. e-Pub 2022. PMID: 35392239.
- Farina M, Bernardi S, Polverelli N, D'Adda M, Malagola M, Bosio K, Re F, Almici C, Dunbar A, Levine RL, Russo D. Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis. Cells 10(10), 2021. e-Pub 2021. PMID: 34685741.
- Ball BJ, Hsu M, Devlin SM, Arcila M, Roshal M, Zhang Y, Famulare CA, Goldberg AD, Cai SF, Dunbar A, Epstein-Peterson Z, Menghrajani KN, Glass JL, Taylor J, Viny AD, Giralt SS, Gyurkocza B, Shaffer BC, Tamari R, Levine RL, Tallman MS, Stein EM. The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy. Am J Hematol 96(5):E171-E175, 2021. e-Pub 2021. PMID: 33650111.
- Dunbar A, Levine RL. "Interferon" with MPN hematopoietic stem cells. Blood 137(16):2129-2130, 2021. e-Pub 2021. PMID: 33885710.
- Dunbar A, Bolton KL, Devlin SM, Sanchez-Vega F, Gao J, Mones JV, Wills J, Kelly D, Farina M, Cordner KB, Park Y, Kishore S, Juluru K, Iyengar NM, Levine RL, Zehir A, Park W, Khorana AA, Soff GA, Mantha S. Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. Blood 137(15):2103-2113, 2021. e-Pub 2021. PMID: 33270827.
- Gerds AT, Gotlib J, Bose P, Deininger MW, Dunbar A, Elshoury A, George TI, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kuykendall AT, McMahon B, Mohan SR, Oehler V, Oh S, Pardanani A, Podoltsev N, Ranheim E, Rein L, Salit R, Snyder DS, Stein BL, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward DC, Bergman MA, Sundar H. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(9):1248-1269, 2020. e-Pub 2020. PMID: 32886902.
- Billon P, Nambiar TS, Hayward SB, Zafra MP, Schatoff EM, Oshima K, Dunbar A, Breinig M, Park YC, Ryu HS, Tschaharganeh DF, Levine RL, Baer R, Ferrando A, Dow LE, Ciccia A. Detection of Marker-Free Precision Genome Editing and Genetic Variation through the Capture of Genomic Signatures. Cell Rep 30(10):3280-3295.e6, 2020. e-Pub 2020. PMID: 32160537.
- Shank K, Dunbar A, Koppikar P, Kleppe M, Teruya-Feldstein J, Csete I, Bhagwat N, Keller M, Kilpivaara O, Michor F, Levine RL, de Vargas Roditi L. Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms. Haematologica 105(3):e91-e94, 2020. e-Pub 2020. PMID: 31413098.
- Bernardi S, Farina M, Zanaglio C, Cattina F, Polverelli N, Schieppati F, Re F, Foroni C, Malagola M, Dunbar AJ, Russo D. ETV6: A Candidate Gene for Predisposition to "Blend Pedigrees"? A Case Report from the NEXT-Famly Clinical Trial. Case Rep Hematol 2020:2795656, 2020. e-Pub 2020. PMID: 32148977.
- Xiao W, Goldberg AD, Famulare CA, Devlin SM, Nguyen NT, Sim S, Kabel CC, Patel MA, McGovern EM, Patel A, Schulman J, Dunbar AJ, Epstein-Peterson ZD, Menghrajani KN, Getta BM, Cai SF, Geyer MB, Glass JL, Taylor J, Viny AD, Levine RL, Zhang Y, Giralt SA, Klimek V, Tallman MS, Roshal M. Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia. Haematologica 104(7):1378-1387, 2019. e-Pub 2019. PMID: 30523054.
- Khan SN, Jankowska AM, Mahfouz R, Dunbar AJ, Sugimoto Y, Hosono N, Hu Z, Cheriyath V, Vatolin S, Przychodzen B, Reu FJ, Saunthararajah Y, O'Keefe C, Sekeres MA, List AF, Moliterno AR, McDevitt MA, Maciejewski JP, Makishima H. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. NIH 6:1301-9, 2013. e-Pub 2013. PMID: 23486531.
- Dunbar A, Gotsis W, Frishman W. Second-hand tobacco smoke and cardiovascular disease risk: an epidemiological review. NIH 21(2):94-100, 2013. e-Pub 2013. PMID: 22968181.
- Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, Muramatsu H, O'Keefe C, Hsi E, Paquette RL, Kojima S, List AF, Sekeres MA, McDevitt MA, Maciejewski JP. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. Europe PMC 27(36):6109-6116, 2009. e-Pub 2009. PMID: 19901108.
- Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, Sekeres M, Saunthararajah Y, Maciejewski JP. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. NIH 113(6):1315-25, 2009. e-Pub 2009. PMID: 18832655.
- Dunbar A, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, Szpurka H, Sekeres MA, Wang XF, McDevitt MA, Maciejewski JP. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies.. NIH 68(24):10349–10357, 2008. e-Pub 2008. PMID: 19074904.
- McIver Z, Serio B, Dunbar A, O'Keefe CL, Powers J, Wlodarski M, Jin T, Sobecks R, Bolwell B, Maciejewski JP. Double-negative regulatory T cells induce allotolerance when expanded after allogeneic haematopoietic stem cell transplantation. Europe PMC 141(2):170-178, 2008. e-Pub 2008. PMID: 18318770.
- Gondek LP, Dunbar AJ, Szpurka H, McDevitt MA, Maciejewski JP. SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. NIH 2(11):e1225, 2007. e-Pub 2007. PMID: 18030353.
- Tiu RV, Mountantonakis SE, Dunbar AJ, Jr SM. Tumor lysis syndrome. NIH 33(4):397-407, 2007. e-Pub 2007. PMID: 17525897.
- Kirsten JH, Xiong Y, Dunbar AJ, Rai M, Singleton CK. Ammonium transporter C of Dictyostelium discoideum is required for correct prestalk gene expression and for regulating the choice between slug migration and culmination. NIH 287(1):146-56, 2005. e-Pub 2005. PMID: 16188250.
Review Articles
- Dunbar A, Park Y, Levine R. Epigenetic Dysregulation of Myeloproliferative Neoplasms. Hematol Oncol Clin North Am 35(2):237-251, 2021. e-Pub 2021. PMID: 33641866.
- Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood 136(1):61-70, 2020. e-Pub 2020. PMID: 32430500.
- Dunbar A, Nazir A, Levine R. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs). Curr Protoc Pharmacol 77:14.40.1-14.40.19, 2017. e-Pub 2017. PMID: 28640953.
Editorials
- Dunbar A, Levine RL. "Interferon" with MPN hematopoietic stem cells. Blood 137(16):2129-2130, 2021. PMID: 33885710.
- Dunbar A, Tallman M. Molecular Minimal Residual Disease Detection Shows Further Promise in Acute Myeloid Leukemia. The ASCO Post, 2018.
Book Chapters
- Dunbar A, Park Y, Levine R. Epigenetic Dysregulation of Myeloproliferative Neoplasms. 35, 237-251, 2021.
- Dunbar AJ, Berman E. Chronic Myelogenous Leukemia. In N. Vasan and M.I. Carlo (Eds.). 2, 2018.
Patient Reviews
CV information above last modified July 31, 2026